Stockscreener 앱 받기
9.36
4.97%
-0.49
시장 영업 전:
9.50
0.14
+1.50%
전일 마감가:
$9.85
열려 있는:
$9.99
하루 거래량:
87,283
Relative Volume:
1.62
시가총액:
$343.47M
수익:
$4.90M
순이익/손실:
$-173.80M
주가수익비율:
-1.9553
EPS:
-4.787
순현금흐름:
$-26.31M
1주 성능:
-4.10%
1개월 성능:
-8.06%
6개월 성능:
+65.37%
1년 성능:
+511.76%
1일 변동 폭
$9.36
$10.95
1주일 범위
$8.78
$10.95
52주 변동 폭
$1.17
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
명칭
Armata Pharmaceuticals Inc
전화
310-655-2928
주소
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
9.36 | 343.47M | 4.90M | -173.80M | -26.31M | -4.787 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-19 | 개시 | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Study maps phage in Armata’s treatment candidate for lung infections - Stock Titan
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - Morningstar
ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92 - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Armata Pharmaceuticals : 2026 Annual Meeting Proxy - marketscreener.com
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
Armata Pharmaceuticals (NASDAQ: ARMP) 2026 proxy details pay, control and going concern risk - Stock Titan
Pfizer Inc. (PFE)Senior Commercial Leader Daniel B. Gilmer, Ph.D. Appointed to Armata Pharmaceuticals Board of DirectorsCertified Trade Ideas - Newser
Armata Pharmaceuticals Appoints Pfizer Executive Daniel B. Gilmer, Ph.D. to Board to Advance Bacteriophage Therapeutics Commercialization 1 - Minichart
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Arm appoints Dr. Daniel Gilmer to Board effective April 24, 2026 - TradingView
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors - PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
ARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today.Geographic Trends - Xã Thanh Hà
ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors.Retail Trader Ideas - UBND thành phố Hải Phòng
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 6.4%Should You Sell? - MarketBeat
Buyback Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stock2026 Retail Activity & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Armata Pharmaceuticals Inc currently under institutional pressureWeekly Profit Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Earnings Beat: Is Armata Pharmaceuticals Inc currently under institutional pressure2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
ARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Armata (ARMP) Stock Ready to Rally | Price at $11.82, Up 16.16%Money Flow - Xã Vĩnh Công
Update Recap: What analysts say about Armata Pharmaceuticals Inc stockEarnings Risk Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Armata Pharmaceuticals, Inc. (TG1N.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail
Armata Pharmaceuticals schedules annual meeting for June 11 - Investing.com
Armata Pharmaceuticals schedules annual meeting for June 11 By Investing.com - Investing.com India
Armata Pharmaceuticals sets June 11, 2026 for annual stockholders meeting - TradingView — Track All Markets
ARMP Technical Analysis & Stock Price Forecast - Intellectia AI
Market Outlook: Is Armata Pharmaceuticals Inc stock a smart retirement pick2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Innoviva (INVA) files 10-K/A adding Armata audited financials and new officer certifications - stocktitan.net
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss By Investing.com - Investing.com Australia
Armata Pharmaceuticals stock edges down on fourth quarter earnings miss - Investing.com
Armata Pharmaceuticals Reports $173.8 Million Net Loss for 2025 Amid Convertible Loan Impact and Impairment Charges - Minichart
Armata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
ARMP Reports Decrease in Grant Revenue for Q4 2025 - GuruFocus
Armata Pharmaceuticals: Advancing Bacteriophage Therapies for Antibiotic-Resistant Bacterial Infections in 2025 - Minichart
Breakout Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stockPrice Action & AI Powered Market Trend Analysis - baoquankhu1.vn
ARMATA PHARMACEUTICALS, INC._December 31, 2025 - SEC.gov
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - Finviz
Armata Pharmaceuticals (NASDAQ: ARMP) advances late-stage phage pipeline with new funding - Stock Titan
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ARMP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Armata Pharmaceuticals Reports Positive Phase 2a Study Results - MSN
HC Wainwright reaffirms buy on Armata Pharmaceuticals, Inc. (ARMP) after FDA nod - MSN
Armata Pharmaceuticals delays Q4 2025 results, gets FDA approval By Investing.com - Investing.com India
Armata Pharmaceuticals Inc (ARMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):